Ceftobiprole medocaril FDA Approval Status
FDA Approved: No
Generic name: ceftobiprole medocaril
Company: Basilea Pharmaceutica Ltd.
Treatment for: Skin and Structure Infection
Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic in development for the treatment of Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Development timeline for ceftobiprole medocaril
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.